Celebrating a lifetime of achievement
LINK: https://nzoptics.co.nz/live-articles/atkinson-awarded/
Lesley Springall2 min read
Advertisement
LINK: https://nzoptics.co.nz/live-articles/atkinson-awarded/
LINK: https://nzoptics.co.nz/live-articles/patients-needed-for-castor-oil-study/
The highly anticipated launch of preservative-free eye drops marked a promising advance in treatment for Glaucoma patients
US researchers have discovered that some over-the-counter glucosamine supplementations are associated with increased intraocular pressure (IOP) and could contribute to the pathogenesis of glaucoma.
A new European research project will pioneer an artificial intelligence (AI) -based programme to identify and monitor age-related macular degeneration (AMD) at its earliest stages. Leveraging A
A Taiwanese review concluded toric IOLs are the preferred choice for astigmatism correction in cataract patients, with femtosecond laser-assisted astigmatic keratotomy (FSAK) serving as a viable alter
Rachel Mackenzlee Mayta lost her eye to retinoblastoma when she was just 18 months old. Determined to end the stigma against visible differences, she’s launched a range of funky prosthetics, including gold glittery ones, on TikTok.
Following a year-long UK pilot of a four-day working week, 51% of participating businesses confirmed they had made the model permanent, while 89% said they continued the policy after the pilot finishe
Results of an international study have demonstrated a shared immune surveillance mechanism between the brain and the eyes.
Ultra-widefield retinal imaging tech company Optos announced the dual milestone of installing 25,000 devices worldwide and the collection of 2,500 peer-reviewed studies spanning 235 disease states.
Biopharmaceutical company Telios Pharma has revealed positive topline results from its phase 2 study of TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with dry eye disease (DED).
US researchers have found patients prescribed acetylcholinesterase inhibitors (AChEIs) to treat Alzheimer’s disease have a lower risk of developing age-related macular degeneration (AMD), compared wit